Investing.com -- Dyne Therapeutics, Inc. (NASDAQ: DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its ...

NEW YORK - CNO Financial Group (NYSE: CNO) reported second-quarter adjusted earnings that slightly exceeded analyst expectations, as the company continues to make progress toward its 2025-2027 return ...

Investing.com -- PTC (NASDAQ: PTC) Therapeutics (NASDAQ: PTCT) stock rose 9% after the company announced that the U.S. Food and Drug Administration (FDA) has approved its drug SEPHIENCE (sepiapterin) ...

CHARLOTTE - Nucor Corporation (NYSE: NUE) reported second-quarter earnings that exceeded analyst expectations, but shares fell 3.8% after the steel producer’s revenue fell short of forecasts and the ...

Investing.com -- Metsera , Inc. (NASDAQ: MTSR ), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, reported a wider-than-expected second quarter loss on Monday, ...

Elevidys is an adeno-associated virus vector-based gene therapy that uses Sarepta’s AAVrh74 Platform Technology to treat DMD, ...

Cadence Design Systems Inc (NASDAQ: CDNS) jumped 7% in recent afterhours trading following the report. For the three months ...

CHARLOTTE - Nucor Corporation (NYSE: NUE) reported second-quarter earnings that exceeded analyst expectations, but shares fell 3.8% after the steel producer’s revenue fell short of forecasts and the ...

The company’s operating profit margin was 22.8%, while adjusted operating profit margin stood at 23.7%. Free cash flow reached $323 million, representing a 34.5% increase from the previous year.

For the full fiscal year 2025, Tilray achieved record revenue of $821.3 million, representing a 4% increase from the previous year. The company’s cannabis segment saw gross margin expansion of 700 ...

Despite the revenue adjustment, Waste Management raised its free cash flow projection to between $2.8 billion and $2.9 ...

Based on its strong performance, Welltower raised its full-year 2025 guidance, now expecting normalized FFO of $5.06 to $5.14 per diluted share, up from the previous range of $4.90 to $5.04. The ...